Osteoarthritis (OA) is the most common form of arthritis worldwide, affecting an estimated 500 million people — yet it is frequently misunderstood as simply "wear and tear." In reality, OA is a complex, whole-joint disease in which mechanical stress, low-grade inflammation, and failed repair processes converge to degrade articular cartilage, remodel subchondral bone, and inflame the synovial lining. Unlike rheumatoid arthritis, which is driven by systemic autoimmunity, OA arises from an imbalance between the joint's capacity to maintain and repair its tissues and the loads placed upon it. Age, obesity, previous injury, and genetic predisposition all tip that balance. For decades, treatment has been palliative — pain relief, physiotherapy, and eventually joint replacement. The question that mesenchymal stem cell (MSC) research is now asking is whether the biology of repair can be meaningfully supported before the joint reaches the surgical endpoint.

What actually happens inside an osteoarthritic joint

The healthy joint is an exquisitely tuned biomechanical system. Articular cartilage — a smooth, resilient tissue that covers the ends of bones — is maintained by chondrocytes, the resident cells that continuously synthesise and remodel the extracellular matrix of collagen and proteoglycans. In OA, this equilibrium breaks. Chondrocytes become senescent — they stop dividing and begin secreting pro-inflammatory cytokines, matrix-degrading enzymes (notably MMP-13 and ADAMTS-5), and reactive oxygen species that further damage the surrounding matrix. Cartilage loses its water-binding proteoglycans, its surface fibrillates, and fissures deepen until bone is exposed.

What was once considered a purely mechanical disease is now understood to have a significant inflammatory component. Synovial macrophages become activated, releasing IL-1β, TNF-α, and IL-6 into the joint space. These cytokines amplify chondrocyte catabolism and sensitise peripheral nociceptors, contributing to the pain that defines the patient's experience. The subchondral bone remodels abnormally, forming sclerotic plates and osteophytes. Critically, unlike in rheumatoid arthritis, this inflammation is low-grade and compartmentalised — it stays largely within the joint rather than becoming systemic. That distinction is important because it shapes what a cell therapy would need to achieve: not systemic immune suppression, but local modulation of a degenerative microenvironment.

Why mesenchymal stem cells are a candidate for osteoarthritis

The rationale for MSCs in OA rests on three overlapping capabilities that map directly onto the disease process. First, MSCs can exert chondroprotective and trophic effects — they secrete growth factors including TGF-β, IGF-1, and BMPs that support the survival and matrix-producing activity of the patient's own chondrocytes. In co-culture experiments, MSCs reduce chondrocyte apoptosis and slow the loss of proteoglycans from cartilage explants exposed to inflammatory stimuli. Second, they are anti-inflammatory — MSCs suppress the activation of synovial macrophages and shift them from a pro-inflammatory (M1) toward a tissue-remodelling (M2) phenotype, thereby lowering the intra-articular concentrations of IL-1β and TNF-α. Third, they provide direct matrix support — although MSCs are not expected to regenerate a pristine articular surface de novo, they can differentiate into chondrocyte-like cells and contribute to the repair tissue that fills cartilage defects, particularly when delivered on a scaffold or in combination with microfracture.

Importantly, MSC therapy for OA is almost always delivered intra-articularly — injected directly into the joint space — unlike the intravenous route used in many systemic autoimmune and inflammatory conditions. This local delivery concentrates the cells where they are needed, reduces systemic exposure, and has contributed to the favourable safety profile observed across dozens of clinical studies.

What the clinical evidence actually shows

The clinical literature on MSCs for knee OA is now substantial — more than for any other MSC indication — and it tells a story that is encouraging but incomplete. Multiple systematic reviews and meta-analyses have aggregated data from randomised controlled trials (RCTs) and concluded that intra-articular MSC injection is associated with statistically significant and clinically meaningful reductions in pain, as measured by the Visual Analogue Scale (VAS) and the WOMAC pain subscale, and with improvements in function that persist for 12 to 24 months in many studies [1][2].

Several individual trials merit attention for what they show — and for what they leave open. A 2015 RCT by Vega and colleagues compared intra-articular allogeneic bone-marrow MSCs against hyaluronic acid in 30 patients and reported significantly better pain and cartilage quality scores (measured by T2 mapping on MRI) in the MSC group at 12 months [3]. A larger 2016 phase I/II multicentre trial by Lamo-Espinosa et al. randomised patients to two different MSC doses or hyaluronic acid alone, finding that the higher dose (100 × 10⁶ cells) produced significant WOMAC and VAS improvements at 12 months compared to the control [4]. In 2019, Matas and colleagues reported a randomised comparison of single versus repeated umbilical-cord MSC injections against hyaluronic acid: the repeated-dose group showed superior pain and function outcomes at 12 months, and importantly, MRI analysis suggested a disease-modifying effect — less progression of cartilage loss in the MSC-treated knees [5].

The cell sources studied are diverse. Bone-marrow-derived MSCs have the longest track record, but umbilical-cord-derived MSCs — which are younger, more proliferative, and avoid the need for a bone-marrow harvest — have produced some of the strongest signals in recent trials [6]. Adipose-derived stromal vascular fraction (SVF) and culture-expanded adipose MSCs have also been widely studied, with meta-analyses suggesting they produce comparable pain relief to bone-marrow MSCs in the short to medium term, though comparative data remain limited [7][8].

The honest headline

As of mid-2026, no MSC product is approved by the FDA or EMA as a standard-of-care treatment for osteoarthritis. The evidence base is considerably stronger than for many other MSC indications — multiple RCTs with consistent pain and function signals — but it has not yet reached the level of regulatory approval. The responsible description is advanced investigational therapy with a growing evidence base, not a proven cure. Any clinic promising guaranteed cartilage regrowth or complete pain resolution is misrepresenting the data.

How OA outcomes are measured — and what MSCs actually move

To weigh the evidence seriously requires knowing what is being measured. In OA trials, the gold-standard patient-reported outcome is the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index), which captures pain, stiffness, and physical function across 24 items. The VAS pain score (0–100 mm) provides a simpler, single-dimension readout. The KOOS (Knee Injury and Osteoarthritis Outcome Score) extends WOMAC to include sports and quality-of-life domains. On the structural side, MRI with T2 mapping and delayed gadolinium-enhanced techniques (dGEMRIC) can quantify cartilage composition and volume, while plain radiographs track joint-space narrowing — though structural change lags symptom change by months to years.

Across the RCTs, the pattern is consistent: MSC-treated groups show greater pain reduction than controls (typically hyaluronic acid or saline) by 6–12 months, with mean VAS improvements in the range of 20–40 mm and WOMAC improvements of 15–25 points — both exceeding the thresholds considered clinically meaningful. Functional gains (stair climbing, walking distance) follow a similar trajectory. The structural data are more preliminary: several trials have reported slower cartilage volume loss or improved T2 relaxation times on MRI, but the effects are modest and not universal [9]. The strongest structural signals have come from trials using repeated dosing rather than a single injection [5].

What the evidence supports — and what it doesn't

A fair reading of the data supports several conclusions. Intra-articular MSC therapy for knee OA has a well-established short- and medium-term safety record, with adverse events generally limited to transient post-injection pain and swelling. It consistently reduces pain and improves function in controlled trials, with effect sizes that are clinically meaningful and appear durable for 12–24 months. There are preliminary structural signals suggesting possible disease modification, but these require confirmation in larger, longer trials with MRI-based primary endpoints.

What the evidence does NOT yet support is equally important. It does not establish that MSCs reverse established OA — grade 4 (bone-on-bone) joints with complete cartilage loss do not regenerate a new cartilage surface. It does not confirm durability beyond 2–3 years, as most trials follow patients for 12–24 months. It does not identify a single optimal protocol — cell source, dose, frequency, and patient selection criteria vary widely across studies. And it does not demonstrate that MSC therapy is superior to total knee arthroplasty for end-stage disease — surgery remains the definitive option when conservative measures have been exhausted.

Osteoarthritis is not a single disease with a single time course — it is a spectrum from early metabolic disturbance to end-stage joint failure. The honest contribution of MSC therapy is likely to be in the middle of that spectrum: slowing progression and reducing symptoms in joints that still have cartilage worth preserving.

— VELAR Clinical Team

How to evaluate any offer responsibly

If you are considering MSC therapy for osteoarthritis, the diligence is straightforward and the same questions protect against over-promise in any medical domain. Ask what cell type and source are used — umbilical-cord MSCs, bone-marrow MSCs, and adipose SVF are biologically different products with different evidence bases. Ask whether the provider can cite published trial data for their specific protocol, not just general references to the field. Ask what outcome measures they use — a provider who tracks your WOMAC and VAS scores before and after treatment is operating with a level of rigour that is absent from clinics offering only testimonials. Ask about cell characterisation: are the cells tested for identity (ISCT criteria: CD73⁺, CD90⁺, CD105⁺, CD45⁻), viability (>90% post-thaw), and sterility before release? Third-party quality data are a meaningful signal of laboratory standards. Be deeply sceptical of guarantees, of claims that grade-4 joints will regenerate cartilage, and of any suggestion that MSC therapy is an alternative to weight management, physiotherapy, and appropriate analgesia — it is an adjunct, not a replacement, for established conservative care.

The VELAR perspective

At VELAR Center, osteoarthritis is one of the conditions we treat most frequently — and precisely because it is common, we believe the standard of evidence required before making any claim is higher, not lower. Our approach is conservative by design: we use umbilical-cord-derived MSCs manufactured under cGMP conditions with ISCT-compliant characterisation and third-party sterility release, we track structured outcomes (WOMAC, VAS, and where indicated, follow-up imaging), and we position MSC therapy as a bridge — a biological intervention that may extend the functional life of a joint and defer arthroplasty — not as a miracle that undoes decades of degeneration. Every consultation begins with an honest conversation about what the evidence says, what it does not say, and whether, given your specific imaging and clinical status, a biologic approach is a rational next step or whether the data suggest you would be better served by other options. That is the standard we would want for our own families, and it is the only standard we offer.

References

  1. Jevotovsky DS, Alfonso AR, Einhorn TA, Chiu ES. Osteoarthritis and stem cell therapy in humans: a systematic review. Osteoarthritis and Cartilage. 2018;26(6):711-729. doi:10.1016/j.joca.2018.02.906 ↩
  2. Ma W, Liu C, Wang S, Xu H, Sun L. Efficacy and safety of mesenchymal stem cell therapy for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Research & Therapy. 2021;12:187. doi:10.1186/s13287-021-02234-6 ↩
  3. Vega A, Martín-Ferrero MA, Del Canto F, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015;99(8):1681-1690. doi:10.1097/TP.0000000000000678 ↩
  4. Lamo-Espinosa JM, Mora G, Blanco JF, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). Journal of Translational Medicine. 2016;14:246. doi:10.1186/s12967-016-0998-2 ↩
  5. Matas J, Orrego M, Amenabar D, et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Stem Cells Translational Medicine. 2019;8(3):215-224. doi:10.1002/sctm.18-0053 ↩
  6. Song Y, Du H, Dai C, et al. Human adipose-derived mesenchymal stem cells for osteoarthritis: a pilot study with long-term follow-up and repeated injections. Regenerative Medicine. 2018;13(3):295-307. doi:10.2217/rme-2017-0152 ↩
  7. Freitag J, Bates D, Boyd R, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy — a review. BMC Musculoskeletal Disorders. 2016;17:230. doi:10.1186/s12891-016-1085-9 ↩
  8. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254-1266. doi:10.1002/stem.1634 ↩
  9. Kim YS, Choi YJ, Lee SW, et al. Assessment of clinical and MRI outcomes after mesenchymal stem cell implantation in patients with knee osteoarthritis: a prospective study. Osteoarthritis and Cartilage. 2016;24(2):237-245. doi:10.1016/j.joca.2015.08.009 ↩
  10. Bastos R, Mathias M, Andrade R, et al. Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. Knee Surgery, Sports Traumatology, Arthroscopy. 2020;28(7):1989-1999. doi:10.1007/s00167-019-05732-8 ↩
  11. Pers YM, Rackwitz L, Ferreira R, et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial. Stem Cells Translational Medicine. 2016;5(7):847-856. doi:10.5966/sctm.2015-0245 ↩
  12. Gupta PK, Chullikana A, Rengasamy M, et al. Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Research & Therapy. 2016;18(1):301. doi:10.1186/s13075-016-1195-4 ↩
  13. Emadedin M, Labibzadeh N, Liastani MG, et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018;20(10):1238-1246. doi:10.1016/j.jcyt.2018.08.005 ↩
  14. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis and Cartilage. 2002;10(3):199-206. doi:10.1053/joca.2001.0504 ↩
  15. Khalifeh Soltani S, Forogh B, Ahmadbeigi N, et al. Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot study. Cytotherapy. 2019;21(1):54-63. doi:10.1016/j.jcyt.2018.11.003 ↩